Indeed, the combination of anti-CTLA4 and anti-PD-1 mAbs is associated with a higher incidence of endocrinopathies (hypothyroidism: 10.2–16.4%; hyperthyroidism: 9.4–10.4%; hypophysitis: 8.8–10.5%; primary adrenal insufficiency: 5.2–7.6%) (3, 4) than the individual use. Here, CTLA4 is linked to hypophysitis.